Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Graft Polymer (UK) PLC ( (GB:SVNS) ) has issued an update.
Solvonis Therapeutics plc announced the allowance of a U.S. patent application for compounds within its AI-enabled CNS discovery program, marking a significant milestone for the company. The patent, expected to be granted soon, will provide U.S. exclusivity through 2043, bolstering Solvonis’ strategic positioning in the neuropsychiatry field by protecting its novel CNS-active compounds. This development enhances the company’s AI-supported drug discovery platform, which focuses on depression, stimulant use disorder, and other neuropsychiatric conditions, and validates the early-stage innovation acquired from Awakn Life Sciences Corp.
More about Graft Polymer (UK) PLC
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing novel medicines for addiction and mental health disorders. Based in London and listed on the London Stock Exchange, Solvonis targets high-burden neuropsychiatric conditions with significant unmet needs, such as Alcohol Use Disorder and Post-Traumatic Stress Disorder. The company is advancing a differentiated pipeline of repurposed and novel compounds, with a capital-efficient model and dual development strategy.
Average Trading Volume: 44,036,262
Technical Sentiment Signal: Hold
Current Market Cap: £10.25M
For an in-depth examination of SVNS stock, go to TipRanks’ Overview page.